With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
In the next round of the eMERGE program, NIH is supporting development of methodologies for integrating genotypic and phenotypic risk scoring into clinical care.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
Working with clinical decision support vendor ActX, the suburban Chicago health system has seen strong demand for PGx and genetically informed preventive care.
In Phase 2 pilots, four healthcare organizations helped HL7 refine its FHIR Genomics specification but uncovered many remaining hurdles to true interoperability.
